Predictive Value of Peripheral Blood Biomarkers in the Treatment of
Lung Cancer Patients with Anti PD-1 Immunotherapy / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 901-909, 2024.
Article
em Zh
| WPRIM
| ID: wpr-1010098
Biblioteca responsável:
WPRO
ABSTRACT
BACKGROUND@#The application of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibodies has greatly improved the clinical outcomes of lung cancer patients. Here, we retrospectively analyzed the efficacy of PD-1 antibody therapy in locally advanced non-surgical or metastatic lung cancer patients, and preliminarily explored the correlation between peripheral blood biomarkers and clinical responses.@*METHODS@#We conducted a single center study that included 61 IIIA-IV lung cancer patients who received PD-1 antibody treatment from March 2020 to December 2021, and collected the medical record data on PD-1 antibody first-line or second-line treatment. The levels of multiple Th1 and Th2 cytokines in the patient's peripheral blood serum, as well as the phenotype of peripheral blood T cells, were detected and analyzed.@*RESULTS@#All the patients completed at least 2 cycles of PD-1 monoclonal antibody treatment. Among them, 42 patients (68.9%) achieved partial response (PR); 7 patients (11.5%) had stable disease (SD); and 12 patients (19.7%) had progressive disease (PD). The levels of peripheral blood interferon gamma (IFN-γ) (P=0.023), tumor necrosis factor α (TNF-α) (P=0.007) and interleukin 5 (IL-5) (P=0.002) before treatment were higher in patients of the disease control rate (DCR) (PR+SD) group than in the PD group. In addition, the decrease in absolute peripheral blood lymphocyte count after PD-1 antibody treatment was associated with disease progression (P=0.023). Moreover, the levels of IL-5 (P=0.0027) and IL-10 (P=0.0208) in the blood serum after immunotherapy were significantly increased compared to baseline.@*CONCLUSIONS@#Peripheral blood serum IFN-γ, TNF-α and IL-5 in lung cancer patients have certain roles in predicting the clinical efficacy of anti-PD-1 therapy. The decrease in absolute peripheral blood lymphocyte count in lung cancer patients is related to disease progression, but large-scale prospective studies are needed to further elucidate the value of these biomarkers.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Biomarcadores
/
Estudos Retrospectivos
/
Interleucina-5
/
Fator de Necrose Tumoral alfa
/
Progressão da Doença
/
Antígeno B7-H1
/
Receptor de Morte Celular Programada 1
/
Imunoterapia
/
Neoplasias Pulmonares
Limite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2024
Tipo de documento:
Article